Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;14(1):92-101.
doi: 10.1111/irv.12697. Epub 2019 Nov 27.

Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

Affiliations
Review

Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

Atin Khalaj-Hedayati et al. Influenza Other Respir Viruses. 2020 Jan.

Abstract

The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.

Keywords: immunogenicity; influenza vaccine; nanoparticles; subunit vaccine; vaccine delivery.

PubMed Disclaimer

Similar articles

Cited by

References

    1. WHO . Influenza fact sheet. 2018. http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed November 6, 2018.
    1. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity. 2006;24(1):5‐9. - PubMed
    1. Blyth CC, Macartney KK, McRae J, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel australian hospitals in 2017: results from the PAEDS‐FluCAN Collaboration. Clin Infect Dis. 2019;68(6):940‐948. 10.1093/cid/ciy597 - DOI - PubMed
    1. Krammer F, Palese P. Influenza virus hemagglutinin stalk‐based antibodies and vaccines. Curr Opin Virol. 2013;3(5):521‐530. - PMC - PubMed
    1. Khurana S, Loving CL, Manischewitz J, et al. Vaccine‐induced anti‐HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114. - PubMed

Publication types

MeSH terms